Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
x
Home
x
Next Post
Previous Post
x
David Dornan, PhD
January 1, 2020
/
Uncategorized
Like
this post!
Share
the Post
About
the Author
Related
Posts
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
cache
Real-world (RW) characterization and frequency of
TSC1
and/or
TSC2
alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer
Read More
Karin Hehenberger, MD, PhD
cache
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success
Analysis of inactivating alterations in
TSC1
and
TSC2
in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
Read More
Anupam Dalal, MD
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.